The escalating war in Iran and the Middle East has disrupted two of the world's most critical logistics corridors—the Strait of Hormuz and major Gulf air hubs—triggering delays across global supply chains. Commercial activity through the Strait of Hormuz remains 90% below pre-war levels as of March 16, and global air-cargo capacity dropped 79% in the Gulf region between February 28 and March 3, driving a 22% reduction worldwide.
The cascading fallout applies to the transport of critical medicines as well, and the consequences underscore a need for acute remedies and long-term structural reform. Immediate responses should focus on visibility of supply-chain gaps across the region and cargo reroutes through non-Gulf hubs. Although imminent medicine shortages are unlikely in the United States given extensive inventory buffers and largely uninterrupted Suez Canal shipping flows, pharmaceutical supply-chain vulnerabilities exposed by the conflict—a dependence on specific transport hubs, fragile cold chains, and emergency supply systems—highlight the need for a longer-term investment in the diversification and streamlining of pharmaceutical supply chains.
Pharmaceutical company executives are responding to the immediate pharmaceutical supply-chain threats by actively targeting unconventional routes to ensure that the delivery of products to their final destinations is uninterrupted. These new journeys include using land routes to truck cargo between airports in the Gulf Cooperation Council (GCC) region or diverting air cargo to China or Singapore to avoid the conflict zone entirely.
